Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease

Caligiuri, 1998, Endothelin-1 inhibits secretin-stimulated ductal secretion by interacting with ETA receptors on large cholangiocytes, Am J Physiol, 275, G835 Jarnagin, 1994, Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis, J Cell Biol, 127, 2037, 10.1083/jcb.127.6.2037 Kinnman, 2003, The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis, Lab Invest, 83, 163, 10.1097/01.LAB.0000054178.01162.E4 Kisseleva, 2006, Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis, J Hepatol, 45, 429, 10.1016/j.jhep.2006.04.014 Russo, 2006, The bone marrow functionally contributes to liver fibrosis, Gastroenterology, 130, 1807, 10.1053/j.gastro.2006.01.036 Wang, 2000, Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat, Hepatology, 31, 428, 10.1002/hep.510310224 Wells, 2004, Autocrine release of TGF-beta by portal fibroblasts regulates cell growth, FEBS Lett, 559, 107, 10.1016/S0014-5793(04)00037-7 Zeisberg, 2007, Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition, J Biol Chem, 282, 23337, 10.1074/jbc.M700194200 Maher, 1990, Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo, J Clin Invest, 86, 1641, 10.1172/JCI114886 Rockey, 1992, Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture, J Submicrosc Cytol Pathol, 24, 193 Arthur, 2000, Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis, Am J Physiol Gastrointest Liver Physiol, 279, G245, 10.1152/ajpgi.2000.279.2.G245 Benyon, 1996, Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver, Gastroenterology, 110, 821, 10.1053/gast.1996.v110.pm8608892 Emonard, 1989, Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasis, Hepatology, 10, 77, 10.1002/hep.1840100116 Friedman, 2007, Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference, Hepatology, 45, 242, 10.1002/hep.21459 Preaux, 1999, Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions, Hepatology, 30, 944, 10.1002/hep.510300432 Takahara, 1995, Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats, Hepatology, 21, 787, 10.1002/hep.1840210328 Garcia-Banuelos, 2002, Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion, Gene Ther, 9, 127, 10.1038/sj.gt.3301647 Siller-Lopez, 2004, Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis, Gastroenterology, 126, 1122, 10.1053/j.gastro.2003.12.045 Issa, 2001, Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors, Gut, 48, 548, 10.1136/gut.48.4.548 Wright, 2001, Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats, Gastroenterology, 121, 685, 10.1053/gast.2001.27188 Zhang, 2006, Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin, J Nutr Biochem, 17, 485, 10.1016/j.jnutbio.2005.09.002 Hadziyannis, 2003, Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B, N Engl J Med, 348, 800, 10.1056/NEJMoa021812 Lai, 1998, A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group, N Engl J Med, 339, 61, 10.1056/NEJM199807093390201 Mallet, 2007, Reversibility of cirrhosis in HIV/HBV coinfection, Antivir Ther, 12, 279, 10.1177/135965350701200201 Abergel, 2004, Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis, Eur J Gastroenterol Hepatol, 16, 1219, 10.1097/00042737-200411000-00022 Poynard, 2002, Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C, Gastroenterology, 122, 1303, 10.1053/gast.2002.33023 Dufour, 1997, Reversibility of hepatic fibrosis in autoimmune hepatitis, Ann Intern Med, 127, 981, 10.7326/0003-4819-127-11-199712010-00006 Ramond, 1992, A randomized trial of prednisolone in patients with severe alcoholic hepatitis, N Engl J Med, 326, 507, 10.1056/NEJM199202203260802 Spahr, 2001, Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood, J Hepatol, 35, 582, 10.1016/S0168-8278(01)00190-8 Blumberg, 1988, Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis, Gastroenterology, 95, 1399, 10.1016/0016-5085(88)90379-4 Powell, 1970, Reversal of “cirrhosis” in idiopathic haemochromatosis following long-term intensive venesection therapy, Australas Ann Med, 19, 54, 10.1111/imj.1970.19.1.54 Wu, 2006, Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients, Hemoglobin, 30, 215, 10.1080/03630260600642534 Hammel, 2001, Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct, N Engl J Med, 344, 418, 10.1056/NEJM200102083440604 Neuschwander-Tetri, 2003, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone, Hepatology, 38, 1008, 10.1053/jhep.2003.50420 Blasco, 2006, Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation, Hepatology, 43, 492, 10.1002/hep.21090 Ekstedt, 2006, Long-term follow-up of patients with NAFLD and elevated liver enzymes, Hepatology, 44, 865, 10.1002/hep.21327 Dienstag, 2006, American Gastroenterological Association technical review on the management of hepatitis C, Gastroenterology, 130, 231, 10.1053/j.gastro.2005.11.010 Strader, 2004, Diagnosis, management, and treatment of hepatitis C, Hepatology, 39, 1147, 10.1002/hep.20119 Rockey, 1996, Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing, J Clin Invest, 98, 1381, 10.1172/JCI118925 Bedossa, 2003, Sampling variability of liver fibrosis in chronic hepatitis C, Hepatology, 38, 1449, 10.1016/j.hep.2003.09.022 O'Brien, 2000, An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C, Am J Clin Pathol, 114, 712, 10.1309/D7AU-EYW7-4B6C-K08Y Pilette, 1998, Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers, J Hepatol, 28, 439, 10.1016/S0168-8278(98)80318-8 Thampanitchawong, 1999, Liver biopsy: complications and risk factors, World J Gastroenterol, 5, 301, 10.3748/wjg.v5.i4.301 Ratziu, 2005, Sampling variability of liver biopsy in nonalcoholic fatty liver disease, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084 Regev, 2002, Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection, Am J Gastroenterol, 97, 2614, 10.1111/j.1572-0241.2002.06038.x Rockey, 2006, Noninvasive measures of liver fibrosis, Hepatology, 43, S113, 10.1002/hep.21046 Poynard, 1997, Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups, Lancet, 349, 825, 10.1016/S0140-6736(96)07642-8 Wai, 2003, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, Hepatology, 38, 518, 10.1053/jhep.2003.50346 Colli, 2003, Severe liver fibrosis or cirrhosis: accuracy of US for detection–analysis of 300 cases, Radiology, 227, 89, 10.1148/radiol.2272020193 Imbert-Bismut, 2001, Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study, Lancet, 357, 1069, 10.1016/S0140-6736(00)04258-6 Callewaert, 2004, Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics, Nat Med, 10, 429, 10.1038/nm1006 McHutchison, 2000, Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group, J Gastroenterol Hepatol, 15, 945, 10.1046/j.1440-1746.2000.02233.x Rockey, 2008, Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography, Gastroenterology, 134, 8, 10.1053/j.gastro.2007.11.053 Sandrin, 2003, Transient elastography: a new noninvasive method for assessment of hepatic fibrosis, Ultrasound Med Biol, 29, 1705, 10.1016/j.ultrasmedbio.2003.07.001 Castera, 2006, FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases, Hepatology, 43, 373, 10.1002/hep.21019 Fraquelli, 2007, Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease, Gut, 56, 968, 10.1136/gut.2006.111302 Ziol, 2005, Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C, Hepatology, 41, 48, 10.1002/hep.20506 Bataller, 2005, Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats, Hepatology, 41, 1046, 10.1002/hep.20665 Bataller, 2003, Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II, Gastroenterology, 125, 117, 10.1016/S0016-5085(03)00695-4 Hirose, 2007, Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis, Hepatology, 45, 1375, 10.1002/hep.21638 Jin, 2007, Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet, Biochem Biophys Res Commun, 364, 801, 10.1016/j.bbrc.2007.10.083 Nabeshima, 2006, Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis, Biochem Biophys Res Commun, 346, 658, 10.1016/j.bbrc.2006.05.183 Rockey, 2003, Vascular mediators in the injured liver, Hepatology, 37, 4, 10.1053/jhep.2003.50044 De, 2003, Portal pressure response to losartan compared with propranolol in patients with cirrhosis, Am J Gastroenterol, 98, 1371, 10.1111/j.1572-0241.2003.07497.x Debernardi-Venon, 2007, AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers, J Hepatol, 46, 1026, 10.1016/j.jhep.2007.01.017 Gonzalez-Abraldes, 2001, Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis, Gastroenterology, 121, 382, 10.1053/gast.2001.26288 Schepke, 2001, Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension, Gastroenterology, 121, 389, 10.1053/gast.2001.26295 Tripathi, 2004, Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis, Am J Gastroenterol, 99, 390, 10.1111/j.1572-0241.2004.04051.x Czaja, 1987, Differential effects of gamma-interferon on collagen and fibronectin gene expression, J Biol Chem, 262, 13348, 10.1016/S0021-9258(18)45207-6 Rockey, 1994, Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis, J Investig Med, 42, 660 Rockey, 1992, Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma, Hepatology, 16, 776, 10.1002/hep.1840160325 Muir, 2006, Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection, J Viral Hepat, 13, 322, 10.1111/j.1365-2893.2005.00689.x Pockros, 2007, Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis, Hepatology, 45, 569, 10.1002/hep.21561 Weng, 2005, Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study, Clin Gastroenterol Hepatol, 3, 819, 10.1016/S1542-3565(05)00404-0 Chevallier, 1994, A histological semiquantitative scoring system for evaluation of hepatic C fibrosis in needle liver biopsy specimens: comparison with morphometric C studies, Hepatology, 20, 349, 10.1002/hep.1840200213 Knodell, 1981, Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis, Hepatology, 1, 431, 10.1002/hep.1840010511 Miyahara, 2000, Peroxisome proliferator-activated receptors and hepatic stellate cell activation, J Biol Chem, 275, 35715, 10.1074/jbc.M006577200 Hazra, 2004, Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells, J Biol Chem, 279, 11392, 10.1074/jbc.M310284200 Yang, 2006, Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis, Am J Physiol Gastrointest Liver Physiol, 291, G902, 10.1152/ajpgi.00124.2006 Lutchman, 2007, The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis, Hepatology, 46, 424, 10.1002/hep.21661 Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326 Di Sario, 2004, The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2, Dig Liver Dis, 36, 744, 10.1016/j.dld.2004.05.012 Di Sario, 2002, Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production, J Hepatol, 37, 584, 10.1016/S0168-8278(02)00245-3 Garcia, 2002, Pirfenidone effectively reverses experimental liver fibrosis, J Hepatol, 37, 797, 10.1016/S0168-8278(02)00272-6 Liu, 2005, Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway, Am J Transplant, 5, 1256, 10.1111/j.1600-6143.2005.00876.x Shimizu, 1998, Pirfenidone improves renal function and fibrosis in the post-obstructed kidney, Kidney Int, 54, 99, 10.1046/j.1523-1755.1998.00962.x Tada, 2001, Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats, Clin Exp Pharmacol Physiol, 28, 522, 10.1046/j.1440-1681.2001.03481.x Azuma, 2005, Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis, Am J Respir Crit Care Med, 171, 1040, 10.1164/rccm.200404-571OC Armendariz-Borunda, 2006, A pilot study in patients with established advanced liver fibrosis using pirfenidone, Gut, 55, 1663, 10.1136/gut.2006.107136 Poo, 1993, Early colchicine administration reduces hepatic fibrosis and portal hypertension in rats with bile duct ligation, J Hepatol, 19, 90, 10.1016/S0168-8278(05)80181-3 Rodriguez, 1998, Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis, Arch Med Res, 29, 109 Rojkind, 1975, Effect of colchicine on collagen, albumin and transferrin synthesis by cirrhotic rat liver slices, Biochim Biophys Acta, 378, 415, 10.1016/0005-2787(75)90186-0 Kaplan, 1986, A prospective trial of colchicine for primary biliary cirrhosis, N Engl J Med, 315, 1448, 10.1056/NEJM198612043152304 Kershenobich, 1988, Colchicine in the treatment of cirrhosis of the liver, N Engl J Med, 318, 1709, 10.1056/NEJM198806303182602 Morgan, 2002, Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: results of a prospective, randomized, placebo-controlled trial, Gastroenterology, 641A Rambaldi, 2001, Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis, Liver, 21, 129, 10.1034/j.1600-0676.2001.021002129.x Miller, 1995, Synthesis of interleukin-1 beta in primary biliary cirrhosis: relationship to treatment with methotrexate or colchicine and disease progression, Hepatology, 22, 518 Nikolaidis, 2006, Colchicine treatment of liver fibrosis, Hepatogastroenterology, 53, 281 Angelico, 2000, Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C, Aliment Pharmacol Ther, 14, 1459, 10.1046/j.1365-2036.2000.00857.x Douglas, 1998, Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group, Am J Respir Crit Care Med, 158, 220, 10.1164/ajrccm.158.1.9709089 Selman, 1998, Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial, Chest, 114, 507, 10.1378/chest.114.2.507 Mandal, 2007, Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis, J Pharmacol Exp Ther, 320, 994, 10.1124/jpet.106.114215 Sakaida, 2003, Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet, J Hepatol, 38, 762, 10.1016/S0168-8278(03)00094-1 Shimizu, 1999, Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats, Hepatology, 29, 149, 10.1002/hep.510290108 Zhang, 2002, Salvia miltiorrhiza monomer IH764-3 induces hepatic stellate cell apoptosis via caspase-3 activation, World J Gastroenterol, 8, 515, 10.3748/wjg.v8.i3.515 Luk, 2007, Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation, Liver Int, 27, 879, 10.1111/j.1478-3231.2007.01527.x Wang, 2000, Treatment of chronic liver diseases with traditional Chinese medicine, J Gastroenterol Hepatol, 15, E67, 10.1046/j.1440-1746.2000.02100.x Stedman, 2002, Herbal hepatotoxicity, Semin Liver Dis, 22, 195, 10.1055/s-2002-30104 Boigk, 1997, Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats, Hepatology, 26, 643, 10.1002/hep.510260316 Jia, 2001, Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1, J Hepatol, 35, 392, 10.1016/S0168-8278(01)00148-9 Lieber, 2003, Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons, J Clin Gastroenterol, 37, 336, 10.1097/00004836-200310000-00013 Ferenci, 1989, Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver, J Hepatol, 9, 105, 10.1016/0168-8278(89)90083-4 Pares, 1998, Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial, J Hepatol, 28, 615, 10.1016/S0168-8278(98)80285-7 Aleynik, 1997, Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis, J Hepatol, 27, 554, 10.1016/S0168-8278(97)80361-3 Lieber, 2003, II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in alcoholic liver disease, Alcohol Clin Exp Res, 27, 1765, 10.1097/01.ALC.0000093743.03049.80 Nava-Ocampo, 1997, Effect of colchiceine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats, Eur J Clin Invest, 27, 77, 10.1046/j.1365-2362.1997.910615.x Combes, 1995, A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis, Hepatology, 22, 759 Degott, 1999, Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression, Hepatology, 29, 1007, 10.1002/hep.510290444 Goulis, 1999, Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis, Lancet, 354, 1053, 10.1016/S0140-6736(98)11293-X Jacquemin, 1997, Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis, Hepatology, 25, 519, 10.1002/hep.510250303 Lindblad, 1998, A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease, Hepatology, 27, 166, 10.1002/hep.510270126 Lindor, 2004, Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial, Hepatology, 39, 770, 10.1002/hep.20092 Poupon, 1999, Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group, Hepatology, 29, 1668, 10.1002/hep.510290603 Poupon, 2003, Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis, J Hepatol, 39, 12, 10.1016/S0168-8278(03)00192-2 Stiehl A, 1994, Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis, Ann Med, 26, 345, 10.3109/07853899409148349 Thompson, 1998, Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis, Hepatology, 28, 1597, 10.1002/hep.510280620 Nelson, 2003, Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect, Hepatology, 38, 859, 10.1053/jhep.2003.50427 Albano, 2008, Oxidative mechanisms in the pathogenesis of alcoholic liver disease, Mol Aspects Med, 29, 9, 10.1016/j.mam.2007.09.004 Brown, 1997, Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload, Am J Physiol, 272, G116 Hasegawa, 2001, Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study, Aliment Pharmacol Ther, 15, 1667, 10.1046/j.1365-2036.2001.01083.x Houglum, 1997, A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C, Gastroenterology, 113, 1069, 10.1053/gast.1997.v113.pm9322499 Mezey, 2003, A randomized placebo controlled trial of vitamin E in alcoholic hepatitis, Hepatology, 38, 264A, 10.1016/S0270-9139(03)80268-9 Stewart, 2002, A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis, J Hepatol, 36, 16, 10.1016/S0168-8278(02)80041-1 Anonymous, 1993, The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group, J Hepatol, 17, 227, 10.1016/S0168-8278(05)80043-1 Rambaldi, 2001, Meta-analysis of propylthiouracil for alcoholic liver disease—a Cochrane Hepato-Biliary Group Review, Liver, 21, 398, 10.1034/j.1600-0676.2001.210606.x Bodenheimer, 1985, A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis, Hepatology, 5, 1139, 10.1002/hep.1840050613 Dickson, 1985, Trial of penicillamine in advanced primary biliary cirrhosis, N Engl J Med, 312, 1011, 10.1056/NEJM198504183121602 Schaff, 1991, The effect of D-penicillamine on CCl4-induced experimental liver cirrhosis, Exp Pathol, 43, 111, 10.1016/S0232-1513(11)80156-8 Lu, 2002, Role of abnormal methionine metabolism in alcoholic liver injury, Alcohol, 27, 155, 10.1016/S0741-8329(02)00226-4 Mato, 1999, S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial, J Hepatol, 30, 1081, 10.1016/S0168-8278(99)80263-3 Aithal, 2004, Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?, Aliment Pharmacol Ther, 19, 391, 10.1046/j.1365-2036.2004.01819.x Nohlgard, 1993, Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis, J Am Acad Dermatol, 28, 40, 10.1016/0190-9622(93)70006-F Te, 2000, Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease, Am J Gastroenterol, 95, 3150, 10.1111/j.1572-0241.2000.03287.x Bach, 2003, Methotrexate therapy for primary biliary cirrhosis, Am J Gastroenterol, 98, 187, 10.1111/j.1572-0241.2003.07173.x Bach, 1998, The histologic effects of low-dose methotrexate therapy for primary biliary cirrhosis, Arch Pathol Lab Med, 122, 342 Hendrickse, 1999, Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial, Gastroenterology, 117, 400, 10.1053/gast.1999.0029900400 Kaplan, 1997, Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment, Ann Intern Med, 126, 682, 10.7326/0003-4819-126-9-199705010-00002 Kaplan, 2004, A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results, Hepatology, 39, 915, 10.1002/hep.20103 Bahcecioglu, 2008, Hepatoprotective effect of Infliximab, an anti-TNF-alpha agent, on carbon tetrachloride-induced hepatic fibrosis, Inflammation, 31, 215, 10.1007/s10753-008-9067-1 Koca, 2008, The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet, Inflammation, 31, 91, 10.1007/s10753-007-9053-z Akriviadis, 2000, Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial, Gastroenterology, 119, 1637, 10.1053/gast.2000.20189 Menon, 2004, A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis, Am J Gastroenterol, 99, 255, 10.1111/j.1572-0241.2004.04034.x Spahr, 2002, Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study, J Hepatol, 37, 448, 10.1016/S0168-8278(02)00230-1 Tilg, 2003, Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis, J Hepatol, 38, 419, 10.1016/S0168-8278(02)00442-7 Boetticher, 2008, Gastroenterology, 134, A765, 10.1016/S0016-5085(08)63572-6 George, 1999, In vivo inhibition of rat stellate cell activation by soluble TGF beta type II receptor: a potential new therapy for hepatic fibrosis, Proc Nat Acad Sci U S A, 96, 12719, 10.1073/pnas.96.22.12719 Isaka, 1996, Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney, Nat Med, 2, 418, 10.1038/nm0496-418 Yata, 2002, Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy, Hepatology, 35, 1022, 10.1053/jhep.2002.32673 Siegmund, 2008, Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis, Am J Physiol Gastrointest Liver Physiol, 294, G357, 10.1152/ajpgi.00456.2007 Hezode, 2005, Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C, Hepatology, 42, 63, 10.1002/hep.20733 Julien, 2005, Antifibrogenic role of the cannabinoid receptor CB2 in the liver, Gastroenterology, 128, 742, 10.1053/j.gastro.2004.12.050 Teixeira-Clerc, 2006, CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis, Nat Med, 12, 671, 10.1038/nm1421 Corpechot, 2002, Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis, Hepatology, 35, 1010, 10.1053/jhep.2002.32524 Tugues, 2007, Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats, Hepatology, 46, 1919, 10.1002/hep.21921 Buck, 2007, A ribosomal S-6 Kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis, PLoS ONE, 2, e1372, 10.1371/journal.pone.0001372 Khimji, 2008, Divergent transforming growth factor-beta signaling in hepatic stellate cells after liver injury: functional effects on ECE-1 regulation, Am J Pathol, 173, 716, 10.2353/ajpath.2008.071121 Beljaars, 2000, Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor, J Biol Chem, 275, 12743, 10.1074/jbc.275.17.12743 Douglass, 2008, Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury, J Hepatol, 49, 88, 10.1016/j.jhep.2008.01.032 Du, 2007, Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats, J Pharmacol Exp Ther, 322, 560, 10.1124/jpet.107.122481 Gonzalo, 2007, Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells, J Pharmacol Exp Ther, 321, 856, 10.1124/jpet.106.114496 Hagens, 2008, Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers, J Pharmacol Exp Ther, 324, 902, 10.1124/jpet.107.132290 Luk, 2007, Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model, Liver Int, 27, 548, 10.1111/j.1478-3231.2007.01452.x Akinc, 2008, A combinatorial library of lipid-like materials for delivery of RNAi therapeutics, Nat Biotechnol, 26, 561, 10.1038/nbt1402 Sato, 2008, Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone, Nat Biotechnol, 26, 431, 10.1038/nbt1396 Wolfrum, 2007, Mechanisms and optimization of in vivo delivery of lipophilic siRNAs, Nat Biotechnol, 25, 1149, 10.1038/nbt1339 van Rooij, 2007, Control of stress-dependent cardiac growth and gene expression by a microRNA, Science, 316, 575, 10.1126/science.1139089 Fiorucci, 2004, The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis, Gastroenterology, 127, 1497, 10.1053/j.gastro.2004.08.001 Liu, 2003, Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis, J Clin Invest, 112, 1678, 10.1172/JCI18945 Rockey, 2005, Antifibrotic therapy in chronic liver disease, Clin Gastroenterol Hepatol, 3, 95, 10.1016/S1542-3565(04)00445-8